ERBB2 and breast cancer: The main adjuvant and neoadjuvant chemotherapy regimens involve [5] the use of anthracyclines (AC), although recently new AC-free schemes are recommended for Her-2 positive BC [6,7] and in postmenopausal women presenting with a luminal-like lobular histotype where an endocrine therapy is preferred [8,9].